British Journal of Rheumatology 1998;37:946–951 IMPROVEMENT IN GASTROINTESTINAL TOLERABILITY OF THE SELECTIVE CYCLOOXYGENASE (COX )-2 INHIBITOR, MELOXICAM, COMPARED WITH PIROXICAM: RESULTS OF THE SAFETY AND EFFICACY LARGE-SCALE EVALUATION OF COX-INHIBITING THERAPIES (SELECT ) TRIAL IN OSTEOARTHRITIS

J. DEQUEKER, C. HAWKEY,* A. KAHAN,† K. STEINBRÜCK,‡ C. ALEGRE,§ E. BAUMELOU,¶ B. BÉGAUD,d H. ISOMÄKI,** G. LITTLEJOHN,†† J. MAU‡‡ and S. PAPAZOGLOU§§ ON BEHALF OF THE SELECT STUDY GROUP Division of Rheumatology, University Hospitals, K.U. Leuven, Belgium, *University Hospital Queen’s Medical Centre, Nottingham, †Hôpital Cochin, Paris, France, ‡Sportklinik Stuttgart, Germany, §Hospital de Enfermedades Reumáticas, Barcelona, Spain, ¶CMS Foch, Suresnes, dHôpital Pellegrin-Carriere, Bordeaux, France, **Rheumatism Foundation Hospital, Heinola, Finland, ††Monash Medical Centre, Victoria, Australia, ‡‡Heinrich-Heine-Universität, Düsseldorf, Germany and §§District General Hospital of Athens, Greece